Benign Prostatic Hyperplasia (BPH)

Trial Status

Protocol Number: 191622-100 07/2010 - Present
Sponsor: Allergan, Inc.
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Study of the Efficacy and Safety of Intraprostatic Administration of Botox® 200 U (Botulinum Toxin Type A) Purified Neurotoxin Complex to Treat Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia.

Purpose of Study
To access the efficacy of intraprostatic administration of Botox® 200 U compared with placebo to treat lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH).

For further information click here.

List of Completed Trials for Benign Prostatic Hyperplasia (BPH)

Protocol Number: H6D-MC-LVHK 07/2006 – 02/2008
Sponsor: Lilly, ICOS, LLC
A randomized, double-blind, placebo controlled, parallel design, multi-center study to evaluate the urodynamic effects of Tadalafil once a day for 12 weeks in men with signs and symptoms of Benign Prostatic Hyperplasia.

Clinical Research Coordinators:
Lisa Bennett, RN or Michelle Utrera, CMA, EMT(336) 274-1114 ext. 5322
E-mail address:

Website Graphics by Vintage Marketing